BioNTech SE (BNTX) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

8/25

Growth 1 Margin 1 Expansion 3 Platform 1 Financial 2

latest quarter score

Earnings Reports

8
BioNTech (BNTX) Q2 2026: Oncology Pipeline Targets 17+ Late-Stage Readouts by 2030 Amid $400M Revenue Guidance Cut
August 04, 2026
8
BioNTech (BNTX) Q1 2026: $1B Buyback and $500M Cost Cuts Signal Oncology Pivot
May 05, 2026
9
BioNTech (BNTX) Q4 2025: Oncology Pipeline Drives €613M BMS Collaboration Revenue Shift
March 10, 2026
10
BioNTech (BNTX) Q3 2025: BMS Collaboration Adds $700M, Anchoring Oncology Pipeline Transition
November 03, 2025
10
BioNTech (BNTX) Q2 2025: $3.5B BMS Milestone Deal Accelerates Oncology Pivot
August 04, 2025
6
BioNTech (BNTX) Q1 2025: Oncology R&D Spend Climbs 4% as BNT327 Moves Toward Pivotal Trials
July 06, 2025
6
BioNTech (BNTX) Q4 2024: Oncology Pipeline Expansion Drives Strategic Transition Despite Revenue Decline
March 10, 2025
BioNTech (BNTX) Q3 2024: Oncology Pipeline Expands With 10+ Phase 2/3 Trials, Fueling R&D Surge
November 04, 2024
BioNTech (BNTX) Q2 2024: R&D Spend Surges 57% as Late-Stage Oncology Pipeline Accelerates
August 05, 2024
BioNTech (BNTX) Q1 2024: R&D Spend Jumps 52% as Oncology Pipeline Accelerates Toward 10 Pivotal Trials
May 06, 2024
BioNTech (BNTX) Q4 2023: R&D Spend to Rise 44% as Oncology Pipeline Targets $10B+ Opportunity
March 20, 2024
BioNTech (BNTX) Q3 2023: R&D Expenses Rise 46% as Oncology Pipeline Enters Late-Stage Trials
November 06, 2023
BioNTech (BNTX) Q2 2023: R&D Spend Cut by €400M as COVID Vaccine Volumes Fall
August 07, 2023
BioNTech (BNTX) Q1 2023: Oncology Pipeline Expands to 27 Programs as COVID Franchise Targets €5B
May 08, 2023
BioNTech (BNTX) Q4 2022: COVID Vaccine Revenue Falls to €17.1B as Commercial Transition Begins
March 27, 2023

Browse all companies